| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1007.5 KB | Adobe PDF |
Authors
Abstract(s)
A osteoartrite é uma doença degenerativa que provoca deterioração da cartilagem, instabilidade e dor articulares. O seu maneio médico é multimodal e inclui prevenção da progressão da doença, bem como gestão dos sinais clínicos. Esta doença está normalmente associada a diversos fatores de risco como a raça, peso, idade avançada, entre outros. Os principais objetivos deste estudo foram descrever o uso de bedinvetmab (Librela) enquanto fármaco de maneio da dor associada a osteoartrite em cães, bem como investigar possíveis efeitos adversos associados à sua administração. Pretendeu se ainda identificar as apresentações clínicas mais comuns que motivaram a recomendação desta terapêutica. Este estudo retrospetivo utilizou uma amostra de 36 cães, cujos resultados foram recolhidos fazendo recurso a um questionário preenchido pelos seus detentores. A maioria dos animais deste estudo eram animais de grande porte (n=21), esterilizados (n=24) e com mais de 8 anos de idade (n=30). Grande parte dos animais já tinha realizado outros tratamentos previamente ao início da terapêutica com bedinvetmab, e iniciaram o tratamento como alternativa para o maneio da dor após terem sido aconselhados pelo seu médico veterinário assistente. Os detentores mostraram-se em grande parte satisfeitos com os efeitos do bedinvetmab (n=24), e ainda com a sua tolerância, apesar de existirem alguns relatos de reações adversas nesta amostra (n=6), que contudo estão em linha com o descrito na bibliografia. Os resultados deste estudo, ainda que a amostra não seja extensa, indicam que o bedinvetmab é uma alternativa viável e segura para o tratamento da osteoartrite, principalmente em animais com comorbilidades ou que apresentem contraindicações para a realização de outras terapêuticas
ABSTRACT - ASSESSMENT OF BEDINVETMAB USE IN THE CLINICAL CONTEXT OF ITS APPLICATION IN THE MANAGEMENT OF PAIN ASSOCIATED WITH OSTEOARTHRITIS IN DOGS - Osteoarthritis is a degenerative disease that causes cartilage deterioration, as well as joint instability and pain. Its medical management is multimodal and includes prevention of disease progression along with managing clinical signs. This disease is usually associated with various risk factors that include the patients’ breed, weight, age, among others. The main goals of this study were to describe the use of bedinvetmab (Librela) as a pain management drug for osteoarthritis-associated joint pain in dogs, and to investigate potential adverse effects related to its administration. Additionally, the study aimed to identify the most common clinical presentations that prompted the recommendation of this treatment. This retrospective study included a total of 36 dogs, whose results were collected through a questionnaire that was filled out by their owners. Most of patients in this study were of large breeds (n=21), neutered (n=24) and over the age of 8 (n=30). A big portion of them had already been prescribed other treatments prior to bedinvetmab and started this as an alternative for pain management after consulting their veterinary practitioners. Owners seemed positively satisfied with the effects of the medication (n=24) as well as its tolerance, even though there were some occurrences of side effects in this sample (n=6), that were however in accordance with what’s described in the literature. Despite the study’s sample not being extensive, the results indicate that bedinvetmab is a viable and safe alternative for treating osteoarthritis, especially in dogs with comorbidities or with contraindications for other treatments
ABSTRACT - ASSESSMENT OF BEDINVETMAB USE IN THE CLINICAL CONTEXT OF ITS APPLICATION IN THE MANAGEMENT OF PAIN ASSOCIATED WITH OSTEOARTHRITIS IN DOGS - Osteoarthritis is a degenerative disease that causes cartilage deterioration, as well as joint instability and pain. Its medical management is multimodal and includes prevention of disease progression along with managing clinical signs. This disease is usually associated with various risk factors that include the patients’ breed, weight, age, among others. The main goals of this study were to describe the use of bedinvetmab (Librela) as a pain management drug for osteoarthritis-associated joint pain in dogs, and to investigate potential adverse effects related to its administration. Additionally, the study aimed to identify the most common clinical presentations that prompted the recommendation of this treatment. This retrospective study included a total of 36 dogs, whose results were collected through a questionnaire that was filled out by their owners. Most of patients in this study were of large breeds (n=21), neutered (n=24) and over the age of 8 (n=30). A big portion of them had already been prescribed other treatments prior to bedinvetmab and started this as an alternative for pain management after consulting their veterinary practitioners. Owners seemed positively satisfied with the effects of the medication (n=24) as well as its tolerance, even though there were some occurrences of side effects in this sample (n=6), that were however in accordance with what’s described in the literature. Despite the study’s sample not being extensive, the results indicate that bedinvetmab is a viable and safe alternative for treating osteoarthritis, especially in dogs with comorbidities or with contraindications for other treatments
Description
Dissertação de Mestrado Integrado em Medicina Veterinária, área científica de Clínica
Keywords
Osteoartrite Cão Dor Analgesia Bedinvetmab Osteoarthritis Dog Pain Pain management Bedinvetmab
Pedagogical Context
Citation
Silva DG. 2025. Avaliação do uso de bedinvetmab no contexto clínico da sua utilização no maneio da dor associada a osteoartrite em cães [dissertação de mestrado]. Lisboa: FMV-Universidade de Lisboa
Publisher
Universidade de Lisboa, Faculdade de Medicina Veterinária